UroGen Pharma Ltd. Income Tax Expense
UroGen Pharma Ltd. (URGN) reported Income Tax Expense of $5.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-08-05
- UroGen Pharma Ltd. income tax expense (benefit) for the quarter ending 2026-06-30 was $5.63M, a 454.58% increase year-over-year.
- UroGen Pharma Ltd. income tax expense (benefit) for the quarter ending 2026-03-31 was -$4.77M, a 1317.35% decline year-over-year.
- UroGen Pharma Ltd. income tax expense (benefit) for the quarter ending 2025-12-31 was -$275.00K, a 110.38% decline year-over-year.
- UroGen Pharma Ltd. income tax expense (benefit) for the quarter ending 2025-09-30 was -$1.05M, a 1258.24% decline year-over-year.
- UroGen Pharma Ltd. income tax expense (benefit) for fiscal 2025 was $78.00K, a 97.25% decline from fiscal 2024.
- UroGen Pharma Ltd. income tax expense (benefit) for fiscal 2024 was $2.83M, a 27.76% decline from fiscal 2023.
- UroGen Pharma Ltd. income tax expense (benefit) for fiscal 2023 was $3.92M, a 123.36% increase from fiscal 2022.
- UroGen Pharma Ltd. income tax expense (benefit) for fiscal 2022 was $1.75M, a 21.12% increase from fiscal 2021.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.63M 10-Q · filed 2026-08-05 | $857.00K 10-Q · filed 2026-08-05 | $582.00K derived: sum of 3 quarters · filed 2026-08-05 | -$472.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$4.77M 10-Q · filed 2026-05-06 | -$5.05M derived: sum of 2 quarters · filed 2026-05-06 | -$6.10M derived: sum of 3 quarters · filed 2026-05-06 | -$5.09M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$275.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$1.33M derived: sum of 2 quarters · filed 2026-03-02 | -$314.00K derived: sum of 3 quarters · filed 2026-08-05 | $78.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | -$1.05M 10-Q · filed 2025-11-06 | -$39.00K derived: sum of 2 quarters · filed 2026-08-05 | $353.00K 10-Q · filed 2025-11-06 | $3.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.01M 10-Q · filed 2026-08-05 | $1.41M 10-Q · filed 2026-08-05 | $4.06M derived: sum of 3 quarters · filed 2026-08-05 | $4.15M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $392.00K 10-Q · filed 2026-05-06 | $3.04M derived: sum of 2 quarters · filed 2026-05-06 | $3.13M derived: sum of 3 quarters · filed 2026-05-06 | $3.17M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $2.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.74M derived: sum of 2 quarters · filed 2026-03-02 | $2.78M derived: sum of 3 quarters · filed 2026-03-02 | $2.83M 10-K · filed 2026-03-02 |
| 2024-09-30 | $91.00K 10-Q · filed 2025-11-06 | $129.00K derived: sum of 2 quarters · filed 2025-11-06 | $183.00K 10-Q · filed 2025-11-06 | $4.04M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $38.00K 10-Q · filed 2025-08-07 | $92.00K 10-Q · filed 2025-08-07 | $3.95M derived: sum of 3 quarters · filed 2025-08-07 | $3.94M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $54.00K 10-Q · filed 2025-05-12 | $3.91M derived: sum of 2 quarters · filed 2025-05-12 | $3.90M derived: sum of 3 quarters · filed 2025-05-12 | $3.95M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $3.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $3.85M derived: sum of 2 quarters · filed 2025-03-10 | $3.90M derived: sum of 3 quarters · filed 2025-03-10 | $3.92M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$9.00K 10-Q · filed 2024-11-06 | $45.00K derived: sum of 2 quarters · filed 2024-11-06 | $66.00K 10-Q · filed 2024-11-06 | $755.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $54.00K 10-Q · filed 2024-08-13 | $75.00K 10-Q · filed 2024-08-13 | $764.00K derived: sum of 3 quarters · filed 2024-08-13 | $1.47M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $21.00K 10-Q · filed 2024-05-13 | $710.00K derived: sum of 2 quarters · filed 2024-05-13 | $1.42M derived: sum of 3 quarters · filed 2024-05-13 | $1.45M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $689.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.40M derived: sum of 2 quarters · filed 2024-03-14 | $1.43M derived: sum of 3 quarters · filed 2024-03-14 | $1.75M 10-K · filed 2024-03-14 |
| 2022-09-30 | $709.00K 10-Q · filed 2023-11-14 | $741.00K derived: sum of 2 quarters · filed 2023-11-14 | $1.07M 10-Q · filed 2023-11-14 | $2.20M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $32.00K 10-Q · filed 2023-08-10 | $357.00K 10-Q · filed 2023-08-10 | $1.49M derived: sum of 3 quarters · filed 2023-08-10 | $1.49M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $325.00K 10-Q · filed 2023-05-11 | $1.46M derived: sum of 2 quarters · filed 2023-05-11 | $1.46M derived: sum of 3 quarters · filed 2023-05-11 | $1.77M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $1.14M derived: sum of 2 quarters · filed 2023-03-24 | $1.45M derived: sum of 3 quarters · filed 2023-03-24 | $1.45M 10-K · filed 2023-03-24 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-10 | $312.00K derived: sum of 2 quarters · filed 2022-11-10 | $312.00K 10-Q · filed 2022-11-10 | $3.69M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $312.00K 10-Q · filed 2022-08-11 | $312.00K 10-Q · filed 2022-08-11 | $3.69M derived: sum of 3 quarters · filed 2022-08-11 | $3.69M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 | $3.37M derived: sum of 2 quarters · filed 2022-05-10 | $3.37M derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $3.37M derived: sum of 2 quarters · filed 2022-03-21 | $3.37M 10-K · filed 2022-03-21 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | ||
| 2018-12-31 | $125.00K 10-K · filed 2020-03-02 | |||
| 2017-12-31 | $19.00K 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |